Table 2. Products in clinical development at the end of the study.
Phase 1 | Phase 2 | Phase 3 | NDA | PPA | Approved | |
ETC | 16 | 18 | 9 | 0 | 24 | 14 |
GTC | 24 | 25 | 10 | 1 | 11 | 3 |
NTC | 7 | 11 | 5 | 0 | 7 | 0 |
Phase 1 | Phase 2 | Phase 3 | NDA | PPA | Approved | |
ETC | 16 | 18 | 9 | 0 | 24 | 14 |
GTC | 24 | 25 | 10 | 1 | 11 | 3 |
NTC | 7 | 11 | 5 | 0 | 7 | 0 |